Sanofi has agreed to pay $315 million to settle claims that it slowed the development of a multiple sclerosis drug to avoid paying investors after the company acquired Genzyme Corp.
The lawsuit, filed by former Genzyme shareholders in 2015, alleged Sanofi intentionally slowed development of Lemtrada, Genzyme's MS drug, to avoid paying the shareholders for regulatory and sales milestones.
The shareholders said they were due between $708 million and $3.8 billion depending on how quickly Lemtrada received FDA approval, according to BioPharma Dive.
The settlement does not include an admission of liability or wrongdoing from Sanofi.
Read the full article here.